Clinical Trials Logo
  1. Home
  2. 22q11.2 Deletion Syndrome
  3. NCT00556530

Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

DiGeorge Syndrome Clinical Trial

Official title:
Genetic Modifiers of 22q11.2 Deletion Syndrome

Clinical Trial Summary

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.

Clinical Trial Description

22q11.2 deletion syndrome is a disorder caused by the deletion of a small piece of chromosome 22. Most people with this disorder are missing a sequence of about 3 million DNA building blocks on chromosome 22 within each cell. This disorder affects many areas of the body. People with 22q11.2 deletion syndrome may have heart defects, immune deficiency, kidney abnormalities, hearing loss, and cleft palate or other facial deformities. Many children experience developmental delays and learning disabilities, and they have an increased risk of developing mental illnesses, including schizophrenia, depression, anxiety, and bipolar disorder. All people with 22q11.2 deletion syndrome are missing the same sequence of DNA, but the severity of this disorder varies widely; some people are diagnosed with multiple health and developmental problems, while others experience very few symptoms. In some people, the symptoms may be so minimal that they are not even aware they have 22q11.2 deletion syndrome. This study will examine genetic material-either from blood or saliva-among people with 22q11.2 deletion syndrome. Participants will attend one study visit and undergo either blood or saliva collection. By analyzing the DNA sequences of participants, the study will aim to identify any genetic variations that may affect the severity of 22q11.2 deletion syndrome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00556530
Study type Observational
Source Albert Einstein College of Medicine
Contact Bernice E. Morrow, PhD
Phone 718-678-1121
Email morrow@aecom.yu.edu
Status Recruiting
Phase
Start date July 2016
Completion date July 2029
View Details
See also
  Status Clinical Trial Phase
Completed NCT00576836 - Thymus Transplantation Dose in DiGeorge #932 Phase 2
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Terminated NCT00395538 - Effects of PTH Replacement on Bone in Hypoparathyroidism Phase 3
Completed NCT02787486 - Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Completed NCT00576407 - Thymus Transplantation in DiGeorge Syndrome #668 Phase 2
Completed NCT00105274 - Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study N/A
Active, not recruiting NCT02430584 - Whole Blood Specimen Collection From Pregnant Subjects
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00579709 - Thymus Transplantation With Immunosuppression Phase 1
Completed NCT00566488 - Parathyroid and Thymus Transplantation in DiGeorge #931 Phase 1
Terminated NCT00278005 - Infection in DiGeorge Following CHD Surgery N/A
Recruiting NCT00005102 - Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome N/A
Completed NCT02381457 - SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
Approved for marketing NCT01220531 - Thymus Transplantation Safety-Efficacy